Tech Company Financing Transactions

NeoPhore Funding Round

NeoPhore closed a $28.5 million Series B funding round on 1/19/2023. Investors included 2Invest, 3B Future Health Fund and Astellas Venture Capital.

Transaction Overview

Company Name
Announced On
1/19/2023
Transaction Type
Venture Equity
Amount
$28,500,000
Round
Series B
Proceeds Purpose
NeoPhore is focused on the discovery and development of novel first-in-class small molecule drugs targeting the DNA mismatch repair (MMR) pathway to treat cancer. The additional funding will be used to progress NeoPhore's expanding pipeline of drugs, encompassing multiple biological targets and modalities of treatment, to the start of IND-enabling studies in 2024.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3rd Floor, 1 Ashley Road, Altrincham
Cheshire, WA14 2DT
UK
Email Address
Overview
Our approach targets the dynamics of cancer neoantigen evolution through the discovery and design of effective, well-tolerated medicines that will become a key part of the next-generation of cancer immunotherapies. Our compounds target components of the MMR pathway that have been validated in both clinical and preclinical studies. These components are known to modulate neoantigen creation and diversity across numerous cancers.
Profile
NeoPhore LinkedIn Company Profile
Social Media
NeoPhore Company Twitter Account
Company News
NeoPhore News
Facebook
NeoPhore on Facebook
YouTube
NeoPhore on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Matthew Baker
  Matthew Baker LinkedIn Profile  Matthew Baker Twitter Account  Matthew Baker News  Matthew Baker on Facebook
Chief Financial Officer
Stephen Over
  Stephen  Over LinkedIn Profile  Stephen  Over Twitter Account  Stephen  Over News  Stephen  Over on Facebook
Chief Scientific Officer
Martin Drysdale
  Martin Drysdale LinkedIn Profile  Martin Drysdale Twitter Account  Martin Drysdale News  Martin Drysdale on Facebook


 

 

Browse more venture capital transactions:

Prev: 1/19/2023: Scrintal venture capital transaction
Next: 1/19/2023: Zitti venture capital transaction

 

Share this article

 


About Our VC Transactions Data

Our team works diligently to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary